Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer

Kazuya Endo, Yoshihiko Maehara, Hideo Baba, Manabu Yamamoto, Shinichi Tomisaki, Akihiro Watanabe, Yoshihiro Kakeji, Keizo Sugimachi

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Background: Levels of serum and plasma metalloproteinases, especially type IV collagenases are important factors related to metastasis and invasion in various human cancer. The clinical significance of serum matrix metalloproteinase 2 (MMP-2, 72 kDa type IV collagenase) and plasma matrix metalloproteinase 9 (MMP-9, 92 kDa type IV collagenase) was evaluated as possible tumor markers in gastric cancer. Materials and Methods: The precursor form of MMP-2 (proMMP-2) in serum and the precursor form of MMP-9 (proMMP-9) in plasma were examined prior to surgery on 70 patients with gastric cancer, one-step sandwich immunoassay (EIA) was used and serum carcinoembryonic antigen (CEA) levels were also examined in the same patients. Normal sera and plasma samples obtained from healthy individuals without cancer were used as controls. Results: ProMMP-2 levels in patients (mean ± standard deviation) with gastric cancer (602 ± 200 μg/l) were significantly higher than levels (542 ± 80 μg/l) in sera from 70 healthy individuals (P < 0.02). Plasma proMMP-9 levels (119 ± 232 μg/l) in patients with cancel were also significantly higher than those (37 ± 13 μg/l) in plasma (P < 0.004). On the other hand there was no significant correlation between CEA and proMMP-2 levels, and between CEA and proMMP-9 levels. Neither proMMP-2 levels nor proMMP-9 levels significantly related to clinicopathologic features. Conclusions: Serum proMMP-2 levels and plasma proMMP-9 levels may serve as tumor markers, independent from known factors and CEA.

Original languageEnglish
Pages (from-to)2253-2258
Number of pages6
JournalAnticancer research
Volume17
Issue number3 C
Publication statusPublished - Aug 13 1997

Fingerprint

Metalloproteases
Matrix Metalloproteinases
Stomach Neoplasms
Serum
Carcinoembryonic Antigen
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Tumor Biomarkers
Collagenases
Immunoassay
Neoplasms
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Endo, K., Maehara, Y., Baba, H., Yamamoto, M., Tomisaki, S., Watanabe, A., ... Sugimachi, K. (1997). Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer research, 17(3 C), 2253-2258.

Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. / Endo, Kazuya; Maehara, Yoshihiko; Baba, Hideo; Yamamoto, Manabu; Tomisaki, Shinichi; Watanabe, Akihiro; Kakeji, Yoshihiro; Sugimachi, Keizo.

In: Anticancer research, Vol. 17, No. 3 C, 13.08.1997, p. 2253-2258.

Research output: Contribution to journalArticle

Endo, K, Maehara, Y, Baba, H, Yamamoto, M, Tomisaki, S, Watanabe, A, Kakeji, Y & Sugimachi, K 1997, 'Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer', Anticancer research, vol. 17, no. 3 C, pp. 2253-2258.
Endo K, Maehara Y, Baba H, Yamamoto M, Tomisaki S, Watanabe A et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer research. 1997 Aug 13;17(3 C):2253-2258.
Endo, Kazuya ; Maehara, Yoshihiko ; Baba, Hideo ; Yamamoto, Manabu ; Tomisaki, Shinichi ; Watanabe, Akihiro ; Kakeji, Yoshihiro ; Sugimachi, Keizo. / Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. In: Anticancer research. 1997 ; Vol. 17, No. 3 C. pp. 2253-2258.
@article{2955820fe0e948e890d5ed1141a4a8f3,
title = "Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer",
abstract = "Background: Levels of serum and plasma metalloproteinases, especially type IV collagenases are important factors related to metastasis and invasion in various human cancer. The clinical significance of serum matrix metalloproteinase 2 (MMP-2, 72 kDa type IV collagenase) and plasma matrix metalloproteinase 9 (MMP-9, 92 kDa type IV collagenase) was evaluated as possible tumor markers in gastric cancer. Materials and Methods: The precursor form of MMP-2 (proMMP-2) in serum and the precursor form of MMP-9 (proMMP-9) in plasma were examined prior to surgery on 70 patients with gastric cancer, one-step sandwich immunoassay (EIA) was used and serum carcinoembryonic antigen (CEA) levels were also examined in the same patients. Normal sera and plasma samples obtained from healthy individuals without cancer were used as controls. Results: ProMMP-2 levels in patients (mean ± standard deviation) with gastric cancer (602 ± 200 μg/l) were significantly higher than levels (542 ± 80 μg/l) in sera from 70 healthy individuals (P < 0.02). Plasma proMMP-9 levels (119 ± 232 μg/l) in patients with cancel were also significantly higher than those (37 ± 13 μg/l) in plasma (P < 0.004). On the other hand there was no significant correlation between CEA and proMMP-2 levels, and between CEA and proMMP-9 levels. Neither proMMP-2 levels nor proMMP-9 levels significantly related to clinicopathologic features. Conclusions: Serum proMMP-2 levels and plasma proMMP-9 levels may serve as tumor markers, independent from known factors and CEA.",
author = "Kazuya Endo and Yoshihiko Maehara and Hideo Baba and Manabu Yamamoto and Shinichi Tomisaki and Akihiro Watanabe and Yoshihiro Kakeji and Keizo Sugimachi",
year = "1997",
month = "8",
day = "13",
language = "English",
volume = "17",
pages = "2253--2258",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 C",

}

TY - JOUR

T1 - Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer

AU - Endo, Kazuya

AU - Maehara, Yoshihiko

AU - Baba, Hideo

AU - Yamamoto, Manabu

AU - Tomisaki, Shinichi

AU - Watanabe, Akihiro

AU - Kakeji, Yoshihiro

AU - Sugimachi, Keizo

PY - 1997/8/13

Y1 - 1997/8/13

N2 - Background: Levels of serum and plasma metalloproteinases, especially type IV collagenases are important factors related to metastasis and invasion in various human cancer. The clinical significance of serum matrix metalloproteinase 2 (MMP-2, 72 kDa type IV collagenase) and plasma matrix metalloproteinase 9 (MMP-9, 92 kDa type IV collagenase) was evaluated as possible tumor markers in gastric cancer. Materials and Methods: The precursor form of MMP-2 (proMMP-2) in serum and the precursor form of MMP-9 (proMMP-9) in plasma were examined prior to surgery on 70 patients with gastric cancer, one-step sandwich immunoassay (EIA) was used and serum carcinoembryonic antigen (CEA) levels were also examined in the same patients. Normal sera and plasma samples obtained from healthy individuals without cancer were used as controls. Results: ProMMP-2 levels in patients (mean ± standard deviation) with gastric cancer (602 ± 200 μg/l) were significantly higher than levels (542 ± 80 μg/l) in sera from 70 healthy individuals (P < 0.02). Plasma proMMP-9 levels (119 ± 232 μg/l) in patients with cancel were also significantly higher than those (37 ± 13 μg/l) in plasma (P < 0.004). On the other hand there was no significant correlation between CEA and proMMP-2 levels, and between CEA and proMMP-9 levels. Neither proMMP-2 levels nor proMMP-9 levels significantly related to clinicopathologic features. Conclusions: Serum proMMP-2 levels and plasma proMMP-9 levels may serve as tumor markers, independent from known factors and CEA.

AB - Background: Levels of serum and plasma metalloproteinases, especially type IV collagenases are important factors related to metastasis and invasion in various human cancer. The clinical significance of serum matrix metalloproteinase 2 (MMP-2, 72 kDa type IV collagenase) and plasma matrix metalloproteinase 9 (MMP-9, 92 kDa type IV collagenase) was evaluated as possible tumor markers in gastric cancer. Materials and Methods: The precursor form of MMP-2 (proMMP-2) in serum and the precursor form of MMP-9 (proMMP-9) in plasma were examined prior to surgery on 70 patients with gastric cancer, one-step sandwich immunoassay (EIA) was used and serum carcinoembryonic antigen (CEA) levels were also examined in the same patients. Normal sera and plasma samples obtained from healthy individuals without cancer were used as controls. Results: ProMMP-2 levels in patients (mean ± standard deviation) with gastric cancer (602 ± 200 μg/l) were significantly higher than levels (542 ± 80 μg/l) in sera from 70 healthy individuals (P < 0.02). Plasma proMMP-9 levels (119 ± 232 μg/l) in patients with cancel were also significantly higher than those (37 ± 13 μg/l) in plasma (P < 0.004). On the other hand there was no significant correlation between CEA and proMMP-2 levels, and between CEA and proMMP-9 levels. Neither proMMP-2 levels nor proMMP-9 levels significantly related to clinicopathologic features. Conclusions: Serum proMMP-2 levels and plasma proMMP-9 levels may serve as tumor markers, independent from known factors and CEA.

UR - http://www.scopus.com/inward/record.url?scp=0030800319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030800319&partnerID=8YFLogxK

M3 - Article

C2 - 9216697

AN - SCOPUS:0030800319

VL - 17

SP - 2253

EP - 2258

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 C

ER -